The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany

Abstract Background We analysed the impact of clinical study design for oncological pharmaceuticals on the subsequent price negotiations after early benefit assessment between pharmaceutical companies and the German National Association of Statutory Health Insurance Funds. The analysis was conducted...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: C. M. Dintsios, I. Beinhauer
פורמט: Artigo
שפה:Inglês
יצא לאור: BMC 2020-03-01
סדרה:Health Economics Review
נושאים:
Study design
Negotiated prices
Oncological drugs
Pharmaceutical companies
Payers
German statutory health insurance
גישה מקוונת:http://link.springer.com/article/10.1186/s13561-020-00263-2
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים